Tasnim Khessib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tasnim Khessib has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrei Iagaru
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA
1 shared publication Benjamin Md Franc
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology
1 shared publication- Daniel Scott Hippe
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
1 shared publication Eric Yang
Division of Surgical Pathology, Department of Pathology, Stanford Health Care, Palo Alto, CA
1 shared publicationFarshad Moradi
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology
1 shared publication- Fatemeh Behnia
Department of Radiology, Nuclear Medicine Division, University of Washington, Seattle, Wash
1 shared publication
Latest Publications
- 11 February 2024
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 54 (2) , 270-292
Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review
- 11 February 2024
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 54 (2) , 270-292
Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review
- Open Access
- 30 August 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (11) , 3945-3948
Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
- 30 August 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (11) , 3945-3948
Open AccessNeuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
- 1 February 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (4) , e165-e166
Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. 18F-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on 18F-FDG PET/CT is important for prompt cessation of treatment.
- 1 February 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (4) , e165-e166
Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. 18F-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on 18F-FDG PET/CT is important for prompt cessation of treatment.
- 1 July 2022
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 51 (4) , 474-477
Testicular FDG Uptake on PET/CT in Patients with Lymphoma: Correlation with Age
- 1 July 2022
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 51 (4) , 474-477
Testicular FDG Uptake on PET/CT in Patients with Lymphoma: Correlation with Age